Numinus Wellness Inc. logo

Numinus Wellness Inc. (LR23)

Market Open
13 Feb, 12:00
XFRA XFRA
0. 03
-0
-0%
- Market Cap
- P/E Ratio
0% Div Yield
0 Volume
0 Eps
0.03
Previous Close
Day Range
0.03 0.03
Year Range
0.01 0.09
Earnings results expected in 59 days

Summary

LR23 trading today lower at €0.03, a decrease of 0% from yesterday's close, completing a monthly decrease of 0% or €0. Over the past 12 months, LR23 stock gained 10.21%.
LR23 is not paying dividends to its shareholders.
The last earnings report, released on Jan 13, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Apr 14, 2025.
The stock of the company had never split.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on XFRA (EUR).
Want to track LR23 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

LR23 Chart

Numinus Wellness Inc. (LR23) FAQ

What is the stock price today?

The current price is €0.03.

On which exchange is it traded?

Numinus Wellness Inc. is listed on TSX.

What is its stock symbol?

The ticker symbol is LR23.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 0.

When is the next earnings date?

The next earnings report will release on Apr 14, 2025.

Has Numinus Wellness Inc. ever had a stock split?

No, there has never been a stock split.

Numinus Wellness Inc. Profile

Medical Care Facilities Industry
Healthcare Sector
Mr. Payton Nyquvest CEO
XFRA Exchange
CA67054W1032 ISIN
US Country
- Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Numinus Wellness Inc. is at the forefront of integrating traditional mental health treatments with innovative psychedelic-assisted psychotherapy. With operations spanning across Canada and the United States, Numinus provides a comprehensive suite of services aimed at addressing a broad spectrum of mental health issues. The company distinguishes itself through its multifaceted approach which includes clinical research, a network of clinics in Canada and the U.S., and groundbreaking laboratory services focused on the development and application of psychedelic substances for therapeutic use. Founded in 1964 and headquartered in Vancouver, Canada, Numinus leverages its decades of experience to push the boundaries of mental wellness therapies.

Products and Services

Numinus Wellness Inc. offers a wide range of products and services designed to cater to various aspects of mental wellness and psychedelic-assisted therapy:

  • Clinical Research Operations: This segment provides comprehensive clinical research management services tailored for academic institutions and biotechnology companies. It encompasses the development, execution, and supervision of clinical trials aimed at exploring the therapeutic potentials of psychedelics.
  • Canadian Clinic Network: In Canada, Numinus operates a network of clinics delivering a diverse array of clinical services. These include but are not limited to traditional therapy and counseling, ketamine-assisted therapies specifically for depression, broader psychedelic-assisted therapies, mindfulness programs, virtual psychotherapy services, and neurological care. This holistic approach to mental health care underlines the company's commitment to innovative and accessible treatments.
  • U.S. Clinic Network: Numinus extends its innovative approach to therapy into the United States, where its clinics offer similar psychedelic-assisted therapies. Additionally, services such as transcranial magnetic stimulation, psychiatric and medical model management further diversify the company's portfolio in the U.S., making varied and effective treatments more accessible to a wider audience.
  • Laboratory Services: A pioneering facet of Numinus is its expansive laboratory operations. These encompass the cultivation, production, and extraction of Psilocybe and other psychoactive fungi species. The company is also engaged in the development of proprietary processes and products, controlled psychedelics protocols, and a product development pipeline. These efforts are complemented by an emphasis on safety, efficacy studies, and lab testing services. This robust infrastructure supports the company's research and therapeutic applications, ensuring high standards of quality and innovation.
  • Psychedelic-Assisted Therapy Training Services: Recognizing the need for qualified practitioners in this emerging field of mental health care, Numinus offers specialized training for professionals. This program aims to equip therapists and medical practitioners with the necessary skills and knowledge to safely and effectively conduct psychedelic-assisted therapies, thereby ensuring the highest levels of care and patient outcomes.

Contact Information

Address: 666 Burrard Street, Vancouver, BC, Canada, V6C 2X8
Phone: 833 686 4687